AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study
Recruiting
Observational Study
Coronary Heart Disease (CHD)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 12,000 (estimated)
- Sponsor
- China-Japan Friendship Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Coronary artery disease remains a leading cause of global mortality. Although percutaneous coronary intervention (PCI) improves patient outcomes, the long-term risk of major adverse cardiovascular events (MACE) driven by the progression of non-target lesions (NTLs) remains substantial and continues to increase, while current risk stratification tools remain inadequate for predicting NTL progressio…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Aged 18 years or older;
2. Scheduled for or having undergone PCI;
3. Baseline plasma sample obtainable;
4. Informed consent obtained
Exclusion Criteria:
1. Pregnancy or lactation;
2. Severe hepatic or renal dysfunction;
3. Active autoimmune disease;
4. Missing critical data
Contacts